Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2010

PITTSBURGH, Feb. 24, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2010, as filed with the U.S. Securities and Exchange Commission on Feb. 24, 2011, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724-514-1813.

This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.